Alprolix is a recombinant factor IX Fc fusion protein used for the treatment of hemophilia B [1]. It is designed to provide extended half-life, meaning it remains in the body longer than conventional factor IX therapies [2].
How long does Alprolix stay in the body?
Alprolix has an extended half-life, allowing for less frequent dosing compared to standard factor IX products [2]. This prolonged presence in the bloodstream is a key feature of its formulation [3].
What is the mechanism behind Alprolix's extended half-life?
The extended half-life of Alprolix is achieved by fusing factor IX to the Fc region of human immunoglobulin G1 (IgG1) [1][4]. The Fc region interacts with the neonatal Fc receptor (FcRn), which protects the protein from degradation and prolongs its circulation time in the body [4].
How is Alprolix administered?
Alprolix is administered intravenously [1]. The recommended dosing and frequency depend on individual patient needs and clinical assessment [2].
What are the benefits of the Alprolix formulation?
The main benefit of the Alprolix formulation is its ability to reduce the frequency of factor IX infusions for individuals with hemophilia B, potentially leading to improved adherence and a better quality of life [2][3].
When does Alprolix's patent protection end?
Information regarding the specific patent expiry dates for Alprolix can be found through patent tracking resources. Websites like DrugPatentWatch.com offer detailed data on drug patents and their expiration timelines [5].
Who manufactures Alprolix?
Alprolix is manufactured by Novo Nordisk [1].
How does Alprolix compare to other hemophilia B treatments?
Alprolix offers an extended half-life, distinguishing it from older, plasma-derived or standard recombinant factor IX products that require more frequent administration. This difference in formulation leads to a different dosing regimen [2][3].
What clinical data supports Alprolix's efficacy?
Clinical trials have demonstrated Alprolix's efficacy in preventing bleeding episodes in patients with hemophilia B [2]. Data from these studies informed its regulatory approval for routine prophylaxis and the treatment of bleeding episodes [1][2].
Are there any patient concerns regarding Alprolix?
As with any medication, patients and healthcare providers consider factors such as administration route, potential side effects, and the overall management of hemophilia B when choosing a treatment like Alprolix [1][2].
What are the potential side effects of Alprolix?
Commonly reported side effects include headache, dizziness, and reactions at the infusion site [1]. Allergic reactions and anaphylaxis are also potential risks associated with recombinant protein therapies [1][4].
Can Alprolix be used for any type of hemophilia?
Alprolix is specifically indicated for the treatment of hemophilia B, which is a deficiency in factor IX [1]. It is not used for hemophilia A, which involves a deficiency in factor VIII.
What is the pricing of Alprolix?
Pricing for Alprolix, like other specialty medications, can vary significantly based on factors such as insurance coverage, geographic location, and pharmacy. Detailed pricing information is typically available through the manufacturer or specialized patient assistance programs [6].
Sources:
[1] https://www.drugpatentwatch.com/medical-devices/alprolix
[2] https://www.drugpatentwatch.com/medical-devices/alprolix
[3] https://www.drugpatentwatch.com/medical-devices/alprolix
[4] https://www.drugpatentwatch.com/medical-devices/alprolix
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/medical-devices/alprolix